Evaxion 주가의 최고가, 최저가 및 변동 요약
과거 주가
현재 주가	US$3.17
52주 최고가	US$12.15
52주 최저가	US$2.45
베타	0.26
1개월 변동	-16.36%
3개월 변동	-21.53%
1년 변동	19.17%
3년 변동	-94.97%
5년 변동	-98.87%
IPO 이후 변동	-99.36%

최근 뉴스 및 업데이트

내러티브 업데이트 • Jul 10

EVAX: Future Cancer Vaccine Data Will Drive Bullish Repricing Potential

Analysts have adjusted their price target on Evaxion from $19.75 to $16.00, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples. What’s in the News for Evaxion Evaxion plans to present new preclinical data for its cytomegalovirus vaccine candidate EVX-V1 at the International Herpesvirus Workshop 2026 in Montreal, with the findings intended to guide final antigen selection for a broadly protective CMV vaccine candidate (source: recent news report).

내러티브 업데이트 • Jun 26

EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential

Analysts have lowered their price target on Evaxion from $14.19 to $11.25, reflecting the application of a slightly higher discount rate and more moderate assumptions for revenue growth and profit margin, which in turn leads to a higher expected future P/E. What’s in the News for Evaxion Evaxion reported new preclinical data for EVX-04, an off-the-shelf therapeutic vaccine candidate for acute myeloid leukemia, with poster data set for presentation at the European Hematology Association 2026 Congress in Stockholm, Sweden.

Recent updates

내러티브 업데이트 • Jul 10

EVAX: Future Cancer Vaccine Data Will Drive Bullish Repricing Potential

내러티브 업데이트 • Jun 26

EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential

새로운 내러티브 • Mar 11

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

Catalysts About Evaxion Evaxion is a biotech company that applies its AI-Immunology platform to discover and design vaccines and immunotherapies in oncology, infectious disease and potentially autoimmune conditions. What are the underlying business or industry changes driving this perspective?

Seeking Alpha • May 26

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

Summary Evaxion has demonstrated impressive in-house capabilities for discovering and developing vaccine candidates for both infectious diseases and oncology indications. Partnership with MSD, albeit heavily backloaded, provides considerable validation of Evaxion's value. A potential option exercise by MSD expected later this year would bring in up to $10M. EVAX guides a cash runway into mid-2026, which could be extended into 2027 if MSD exercises options for both partnered candidates (not accounting for potential further business developments). EVAX aims for at least 2 new deals in 2025 and is in the meantime further developing its AI platform to stay ahead of competition. Read the full article on Seeking Alpha

Seeking Alpha • Mar 31

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Summary Evaxion's sophisticated AI Immunology platform aims to outperform competitors in vaccine development, in both oncology and infectious diseases indications. The company has already established three collaborations, including a partnership with MSD, and has raised enough funding to last through 2024. Evaxion's AI models, including EDEN, RAVEN, PIONEER, ObsERV, and AI-DEEP, show promise in identifying protective antigens, designing effective and safe personalized cancer vaccines and predicting which patients will respond. Big pharma interest, pending catalysts in 2024, impressive proof-of-concept preclinical and clinical data are compelling enough for me for a small speculative position. However, the risk of considerably more dilutive funding as well as the very early stage of the pipeline make me give a "Hold" recommendation. Read the full article on Seeking Alpha

Seeking Alpha • Oct 05

Evaxion Biotech names Per Norlén as CEO

Evaxion Biotech (EVAX) said Wednesday Per Norlén joined the firm as CEO on Monday. Norlén is a physician and associate professor with over 20 years in the biotech sector, of which the last decade has been in executive leadership roles.

Seeking Alpha • Sep 21

Evaxion stock rises 11% as enrollment begins in trial of immunotherapy EVX-01 for skin cancer

Evaxion Biotech (EVAX) said it enrolled its first patient in a global phase 2b trial of its immunotherapy EVX-01 to treat melanoma, a type of skin cancer. The trial is being conducted at sites in the the U.S., Europe, and Australia in collaboration with Merck (NYSE:MRK) which is supplying the trial with its blockbuster drug Keytruda, the Danish company said in a Sept. 21 press release. Patients will receive standard of care treatment along with Keytruda in combination with EVX-01. Evaxion added that it is responsible for conducting the trial. The company expects interim topline data in H2 2023. EVAX +11.27% to $2.27 premarket Sept. 21

Seeking Alpha • Aug 10

Evaxion Biotech ADS GAAP EPS of -$0.20 beats by $0.10

Evaxion Biotech ADS press release (EVAX): Q2 GAAP EPS of -$0.20 beats by $0.10. As of June 30, 2022, cash and cash equivalents were $25.3M as compared to $32.2M as of December 31, 2021. We expect our existing cash and cash equivalents, including use of financing facilities, will be sufficient to fund our operating expenses and capital expenditure requirements through at least the next 12 months.

Seeking Alpha • Aug 02

Evaxion Biotech announces new CEO as Lars Wegner resigns

Evaxion Biotech (EVAX) announced Tuesday the resignation of chief executive officer Lars Staal Wegner. The clinical-stage biotech company said Per Norlén, M.D., PhD., has been appointed to succeed Wegner. Norlén is a physician and board certified specialist in clinical pharmacology with over 20 years of working in clinical drug development. Most recently, Dr. Norlén was Chief Executive Officer of Targinta AB and Chief Medical Officer of Xintela AB, Targinta is a wholly owned subsidiary of Xintela, a publicly listed company on the Nasdaq First North Growth Market Stockholm, Sweden. Earlier: Evaxion Biotech to advance DNA vaccine into non-small cell lung cancer indication

주주 수익률

	EVAX	US Biotechs	US 시장
7D	-7.0%	-2.4%	0.7%
1Y	19.2%	35.9%	20.6%

수익률 대 산업: EVAX은 지난 1년 동안 35.9%의 수익을 기록한 US Biotechs 산업보다 저조한 성과를 냈습니다.

수익률 대 시장: EVAX은 지난 1년 동안 20.6%의 수익을 기록한 US 시장과 동일한 성과를 보였습니다.

주가 변동성

Is EVAX's price volatile compared to industry and market?
EVAX volatility
EVAX Average Weekly Movement	9.1%
Biotechs Industry Average Movement	10.4%
Market Average Movement	7.3%
10% most volatile stocks in US Market	16.6%
10% least volatile stocks in US Market	3.2%

안정적인 주가: EVAX는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.

시간에 따른 변동성: EVAX의 주간 변동성은 지난 1년간 16%에서 9%로 감소했습니다.

회사 소개

설립	직원 수	CEO	웹사이트
2008	46	Helen Tayton-Martin	evaxion.ai

임상 단계의 바이오테크 기업인 이박사이언스는 인공지능 기반 면역 백신을 개발하는 회사입니다. 진행성 흑색종 치료를 위한 글로벌 다기관 임상 2상 시험 중인 EVX-01, 고형 종양 치료를 위한 DNA 기반 암 백신인 EVX-03, 급성 골수성 백혈병 치료 1상 시험 중인 치료용 암 백신 후보인 EVX-04를 개발 중입니다. 또한 황색포도상구균에 의한 피부 및 연조직 감염을 표적으로 하는 다성분 예방 백신인 EVX-B1, 임질균을 표적으로 하는 다성분 예방 백신인 EVX-B2, 반복 감염과 관련된 세균 병원체를 표적으로 하는 EVX-B3, 거대세포바이러스 다성분 예방 백신 후보인 EVX-V1 등 전임상 단계에 있는 백신 프로그램도 포함되어 있습니다.

Evaxion A/S 기초 지표 요약

Evaxion의 순이익과 매출은 시가총액과 어떻게 비교됩니까?
EVAX 기초 통계
시가총액	US$26.69m
순이익 (TTM)	-US$9.76m
매출 (TTM)	US$7.53m

3.5x

주가매출비율(P/S)

-2.7x

주가수익비율(P/E)

EVAX는 고평가되어 있습니까?

공정 가치 및 평가 분석 보기

순이익 및 매출

최근 실적 보고서(TTM)의 주요 수익성 지표
EVAX 손익계산서 (TTM)
매출	US$7.53m
매출원가	US$0
총이익	US$7.53m
기타 비용	US$17.28m
순이익	-US$9.76m

최근 보고된 실적

Mar 31, 2026

다음 실적 발표일

Aug 20, 2026

주당순이익(EPS)	-1.17
총이익률	100.00%
순이익률	-129.60%
부채/자본 비율	0%

EVAX의 장기 실적은 어땠습니까?

과거 실적 및 비교 보기

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2026/07/10 17:12
종가	2026/07/10 00:00
수익	2026/03/31
연간 수익	2025/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델에 대한 세부 정보는 당사의 Github 페이지에서 확인하실 수 있으며, 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Evaxion A/S는 6명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
Swayampakula Ramakanth	H.C. Wainwright & Co.
Soumit Roy	JonesTrading Institutional Services, LLC
Debanjana Chatterjee	JonesTrading Institutional Services, LLC

Evaxion (EVAX) 주식 개요

강점

위험 분석

Analyst Price Targets

AI-Driven Vaccine Partnerships And Dark Genome Targets Will Shape Long-Term Opportunity

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

AI Immunology Partnerships And Pipeline Progress Will Drive Long Term Value

Top Community Narratives

The "AI-Immunology" Asymmetric Opportunity – Validated by Merck (MSD)

Top Community Narratives

The "AI-Immunology" Asymmetric Opportunity – Validated by Merck (MSD)

Top Analyst Narratives

AI-Driven Vaccine Partnerships And Dark Genome Targets Will Shape Long-Term Opportunity

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

AI Immunology Partnerships And Pipeline Progress Will Drive Long Term Value

Evaxion A/S 경쟁사

Cyclerion Therapeutics

Apollomics

Harvard Apparatus Regenerative Technology

RenovoRx

가격 이력 및 성과

최근 뉴스 및 업데이트

EVAX: Future Cancer Vaccine Data Will Drive Bullish Repricing Potential

EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential

Evaxion A/S Presents New Preclinical Data For EVX-04, An Off-The-Shelf Therapeutic Vaccine For Acute Myeloid Leukemia

Evaxion A/S Promotes Birgitte Rønø as Chief Scientific and Chief Operating Officer

Evaxion A/S Demonstrates Scalability of Ai-Immunology Platform in Glioblastoma

Evaxion A/S Elects Jens Bitsch Nørhave to the Board of Directors

Recent updates

EVAX: Future Cancer Vaccine Data Will Drive Bullish Repricing Potential

EVAX: AI-Immunology Pipeline Progress Will Drive Future Upside Potential

Evaxion A/S Presents New Preclinical Data For EVX-04, An Off-The-Shelf Therapeutic Vaccine For Acute Myeloid Leukemia

Evaxion A/S Promotes Birgitte Rønø as Chief Scientific and Chief Operating Officer

Evaxion A/S Demonstrates Scalability of Ai-Immunology Platform in Glioblastoma

Evaxion A/S Elects Jens Bitsch Nørhave to the Board of Directors

Evaxion A/S Announces Last Patient Visit in One-Year Extension of Phase 2 Trial with Personalized Cancer Vaccine Evx-01

Evaxion A S Presents Novel AI Based Polio Vaccine Design Concepts and Evx V1 Cmv Vaccine Program

Evaxion A/S, Annual General Meeting, Apr 16, 2026

AI Immunology Platform Will Face Partnership Risks Yet Eventually Reward Long-Term Patience

Evaxion A/S Expands AI-Immunology Platform Into Autoimmune Diseases

Evaxion A/S to Report Q3, 2026 Results on Nov 19, 2026

Evaxion A/S to Report Q3, 2025 Results on Nov 06, 2025

Evaxion A/S Announces Dr Helen Tayton-Martin Stepping Down from the Board

Evaxion A/S Announces New Two-Year Unprecedented Clinical Efficacy Data of Its Personalized Cancer Vaccine EVX-01 in Patients with Advanced Melanoma

Evaxion A/S to Present New Biomarker Data for AI- Designed Personalized Cancer Vaccine EVX-01 At the SITC 2025 Annual Meeting

Evaxion A/S to Report Q2, 2025 Results on Aug 14, 2025

Evaxion A/S to Present Two-Year Clinical Efficacy Data from Phase 2 Trial with AI- Designed Personalized Cancer Vaccine EVX-01 at the ESMO Congress 2025

Evaxion A/S Announces CEO Changes

Evaxion Expands R&D Pipeline with New Vaccine Program Targeting Group A Streptococcus

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

Evaxion A/S to Report Q1, 2025 Results on May 27, 2025

Evaxion Doses First Patient in Extension of Phase 2 Trial Exploring the Full Potential of Ai- Designed Personalized Cancer Vaccine Evx-01

Evaxion Biotech A/S Presents striking EVX-01 Data at the AACR Annual Meeting

Evaxion Biotech A/S, Annual General Meeting, Apr 30, 2025

Evaxion Biotech A/S has completed a Follow-on Equity Offering in the amount of $4.48 million.

Evaxion Biotech A/S Extends Phase 2 Trial with AI-Immunology™?

Nasdaq Confirms Evaxion Is Fully Compliant, Withdraws Delisting Determination

Evaxion Completes Dosing in Phase 2 Trial with Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S Establishes New AI-Derived Precision Cancer Vaccine Concept

Evaxion Biotech A/S has filed a Follow-on Equity Offering in the amount of $12.5 million.

Evaxion Announces Positive Preclinical Data for Cytomegalovirus (CMV) Vaccine Program EVX-V1

Evaxion Update on Nasdaq Notification Regarding Minimum Stockholders’ Equity Requirement

Evaxion Biotech A/S to Report Q3, 2024 Results on Oct 31, 2024

Evaxion Biotech A/S Announces Strong Validation of Ai-Immunology Platform in Multiple Clinical Trials

Evaxion Biotech A/S Continues to Grows Clinical Evidence for the Steady Improvement of Its Ai-Immunology Platform

Evaxion Biotech A/S Reports Convincing One-Year Data from Phase 2 Trial on AI-Designed Personalized Cancer Vaccine EVX-01

Evaxion Biotech A/S Reports 69% Overall Response Rate in its Phase 2 Trial on Lead Cancer Vaccine Candidate EVX-01

Consensus revenue estimates increase by 331%

Evaxion Biotech A/S to Report Q2, 2024 Results on Aug 14, 2024

Evaxion Biotech A/S Announces Publication of Data from Its Phase 1 Dose Escalation Study of Its Lead Personalized Cancer Vaccine, EVX-01

Consensus revenue estimates decrease by 97%, EPS upgraded

Consensus revenue estimates decrease by 24%, EPS upgraded

New major risk - Financial position

Evaxion Biotech A/S to Present New Positive Data from Ongoing Phase 2 Study on Lead Vaccine Candidate EVX-01 at the American Society of Clinical Oncology Annual Meeting 2024

Evaxion Announces Phase 2 Clinical Trial Update

Evaxion and Undisclosed Collaborator Announce Encouraging Results for Evx-B1 Vaccine Antigens Against Staphylococcus Aureus Infection

Consensus revenue estimates increase by 33%, EPS downgraded

Evaxion: An Intriguing AI Vaccine Company With Big Pharma Collaboration

Evaxion Biotech A/S, Annual General Meeting, Apr 16, 2024

Forecast to breakeven in 2025